News

Public · Published

Canaccord Genuity maintains Regeneron Pharmaceuticals at Buy, raises price target to $1175 from $922

Canaccord Genuity kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1175 from $922. The new target is 27.4% higher and implies 26.6% upside from the October 30 closing price of $927.89.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1175 from $922. The new target is 27.4% higher and implies 26.6% upside from the October 30 closing price of $927.89.

Confirmed

Global impact / market context

A price target is an analyst’s estimate, not a guaranteed share price. The higher estimate signals greater expected value from Canaccord’s perspective; if investors agree, it could support demand for Regeneron shares, while any gap between expectations and results could instead weaken confidence.

Analyst inference

The supplied article lists five other recent analyst targets ranging from $825 to $1050, below Canaccord’s new $1175 target. This places Canaccord’s view above the cited range, but the article gives no reasons for the change or new company operating results.

Confirmed

What to watch

  1. Watch for Regeneron’s reported business results and any explanation from Canaccord; these could show whether the higher target reflects changed expectations for sales, costs, or other factors. Analyst inference
  2. Compare future analyst targets with the cited $825–$1050 range and Canaccord’s $1175 target; further increases or cuts would show whether views are converging or diverging. Analyst inference
  3. The article reports a Buy rating and target change only; it does not specify a company announcement, forecast change, or operating development behind Canaccord’s decision. Confirmed

Evidence

  • Original source link unavailable